【Abstract】Objective To explore the correlation between plasma fibroblast growth factor 23 (FGF23) level and left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD). Methods Sixty-four CKD patients (16 cases at CKD stages 1~2, 16 cases at CKD stage 3, 16 cases at CKD stage 4, and 16 cases at CKD stage 5) admitted to the Affiliated Hospital of North Sichuan Medical College during October 2016 to October 2017 were recruited in this study. Thirty-two normal individuals in our hospital were selected as the normal controls. Plasma FGF23 was assayed by ELISA method. Left ventricular mass index (LVMI)

was calculated from echocardiography. The relationship between plasma FGF23 level, LVMI and clinical data was analyzed by correlation analyses. Results ① Plasma FGF23 was significantly higher in CKD patients than in normal control group (6.74±6.16ng/ml vs. 1.22±0.19ng/ml; t=-0.348, P=0.001). Plasma FGF23 level increased gradually with the development of CKD, suggesting that plasma FGF23 level may reflect the extent of renal damage. ②The prevalence of LVH was 39.06% in CKD patients. ③ Pearson correlation analysis showed that plasma FGF23 level was positively correlated with LVMI (r=0.372, P= 0.002) and was the independent risk factor for LVH. ④ Multivariate stepwise linear regression also showed that plasma FGF23 was the independent risk factor for LVMI (B=0.272, t=2.272, P=0.027). Therefore, FGF23 is expected to be a therapeutic

target for cardiovascular disease in CKD patients to increase their survival rate.